0001209191-20-031881.txt : 20200522 0001209191-20-031881.hdr.sgml : 20200522 20200522200040 ACCESSION NUMBER: 0001209191-20-031881 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200520 FILED AS OF DATE: 20200522 DATE AS OF CHANGE: 20200522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wigzell Hans Lennart Rudolf CENTRAL INDEX KEY: 0001492766 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 20907675 MAIL ADDRESS: STREET 1: OSKAR BAECKSTROMSV.11 CITY: HAGERSTEN STATE: V7 ZIP: 12935 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-20 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001492766 Wigzell Hans Lennart Rudolf 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2020-05-20 4 M 0 5000 10.08 A 18792 D Common Stock 2020-05-20 4 S 0 2100 149.62 D 16692 D Common Stock 2020-05-20 4 S 0 2046 151.22 D 14646 D Common Stock 2020-05-20 4 S 0 854 151.77 D 13792 D Stock Oprion (right to buy) 10.08 2020-05-20 4 M 0 5000 0.00 D 2013-08-23 2022-08-23 Common Stock 5000 0 D The shares were sold in transactions at prices ranging from $149.11 to $149.89, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares were sold in transactions at prices ranging from $150.62 to $151.62, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares were sold in transactions at prices ranging from $151.67 to $151.75, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. /s/ David Tyronne Howton, as attorney-in-fact for Hans Lennart Rudolf Wigzell 2020-05-22